Related Experiment Video
Updated: Jun 13, 2025
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer
Farhan Haq1, Samudra Sabari1, Jaromir Háček2
1Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Sweden.
Background:
The tumoricidal complex alpha1-oleate targets bladder cancer cells, triggering rapid, apoptosis-like tumor cell death. Clinical effects of alpha1-oleate were recently observed in patients with non-muscle invasive bladder cancer (NMIBC), using a randomized, placebo-controlled study protocol.
Aims:
To investigate if there are dose-dependent effects of alpha1-oleate.
Materials And Methods:
Here, patients with NMIBC were treated by intravesical instillation of increasing concentrations of alpha1-oleate (1.7, 8.5, or 17 mM) and the treatment response was defined relative to a placebo group.
Results:
Strong, dose-dependent anti-tumor effects were detected in alpha1-oleate treated patients for a combination of molecular and clinical indicators; a complete or partial response was detected in 88% of tumors treated with 8.5 mM compared to 47% of tumors treated with 1.7 mM of alpha1-oleate. Uptake of alpha1-oleate by the tumor triggered rapid shedding of tumor cells into the urine and cell death by an apoptosis-like mechanism. RNA sequencing of tissue biopsies confirmed the activation of apoptotic cell death and strong inhibition of cancer gene networks, including bladder cancer related genes. Drug-related side effects were not recorded, except for local irritation at the site of instillation.
Discussion And Conclusions:
These dose-dependent anti-tumor effects of alpha1-oleate are promising and support the potential of alpha1-oleate treatment in patients with NMIBC.
Insights
Alpha1-oleate shows promising dose-dependent anti-tumor effects in non-muscle invasive bladder cancer (NMIBC) patients. Higher doses led to significant tumor response and apoptosis-like cell death with minimal side effects.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Alpha1-oleate is a tumoricidal complex that induces apoptosis-like cell death in bladder cancer.
- Previous studies showed clinical effects of alpha1-oleate in non-muscle invasive bladder cancer (NMIBC) patients.
Purpose of the Study:
- To investigate the dose-dependent effects of alpha1-oleate in NMIBC patients.
Main Methods:
- Patients with NMIBC received intravesical instillation of alpha1-oleate at concentrations of 1.7, 8.5, or 17 mM.
- Treatment response was evaluated against a placebo group.
Main Results:
- Significant, dose-dependent anti-tumor effects were observed.
- An 88% response rate was seen with 8.5 mM alpha1-oleate compared to 47% with 1.7 mM.
- RNA sequencing confirmed apoptosis activation and inhibition of cancer gene networks; minimal side effects were noted.
Conclusions:
- Alpha1-oleate exhibits promising dose-dependent anti-tumor activity in NMIBC.
- These findings support the potential of alpha1-oleate as a treatment for NMIBC.
